Premium
Plasmablastic lymphoma of the elderly: a clinicopathological comparison with age‐related Epstein–Barr virus‐associated B cell lymphoproliferative disorder
Author(s) -
Liu Fang,
Asano Naoko,
Tatematsu Akiko,
Oyama Takashi,
Kitamura Kunio,
Suzuki Kotaro,
Yamamoto Kazuhito,
Sakamoto Natsumi,
Taniwaki Masafumi,
Kinoshita Tomohiro,
Nakamura Shigeo
Publication year - 2012
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2012.04339.x
Subject(s) - plasmablastic lymphoma , lymphoma , lymphoproliferative disorders , medicine , epstein–barr virus , virus , histopathology , b cell , immunodeficiency , immunology , pathology , antibody , immune system
Liu F, Asano N, Tatematsu A, Oyama T, Kitamura K, Suzuki K, Yamamoto K, Sakamoto N, Taniwaki M, Kinoshita T & Nakamura S
(2012) Histopathology
Plasmablastic lymphoma of the elderly: a clinicopathological comparison with age‐related Epstein–Barr virus‐associated B cell lymphoproliferative disorder Aims: Plasmablastic lymphoma (PBL) is an aggressive lymphoma with a terminally differentiated B cell phenotype; half of patients with this disease have Epstein–Barr virus (EBV) infection. The majority of PBL cases are associated with human immunodeficiency virus (HIV) infection, while the remaining HIV‐negative cases were accompanied by other immunodeficiency conditions or immunosenescence in the elderly. Methods and results: To characterize HIV‐negative PBL of the elderly (PBL‐E), we compared the clinicopathological characteristics of 10 cases of PBL‐E and 124 cases with age‐related EBV‐associated B cell lymphoproliferative disorder (AR‐EBVLPD). The 10 PBL‐E (eight men, two women; median age: 68 years) were associated with a more indolent clinical behaviour and a better overall survival than AR‐EBVLPD. Extranodal involvement was higher in PBL‐E (50%) than AR‐EBVLPD; notably, the nasal cavity was affected most frequently in PBL‐E (60%). Immunoglobulin heavy chain/(IGH)/MYC translocation was detected in half of the PBL‐E cases. Conclusions: PBL‐E shares some clinical features with AR‐EBVLPD, such as HIV negativity, old age, and EBV infection, no known immunosuppressive condition but there are some differences such as a higher ratio of extranodal involvement and better prognosis. PBL‐E is a newly recognized condition and should be distinguished from HIV‐positive PBL, sharing features with AR‐EBVLPD in particular, immunosenescence of the elderly.